Novartis AG ADR buy melinda
Start price
25.05.19
/
50%
€79.30
Target price
04.11.21
€90.20
Performance (%)
-8.45%
End price
05.11.21
€72.60
Summary
This prediction ended on 05.11.21 with a price of €72.60. With a performance of -8.45%, the BUY prediction for Novartis AG ADR by melinda closed slightly in the red. A total of €5.57 was paid as dividends for this prediction. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | 1.481% | 1.481% | 36.318% | 44.515% |
| iShares Core DAX® | 0,85 % | 0,39 % | 2,53 % | 52,00 % |
| iShares Nasdaq 100 | -0,99 % | -4,40 % | 25,15 % | 77,54 % |
| iShares Nikkei 225® | -1,78 % | -11,22 % | 44,40 % | 64,68 % |
| iShares S&P 500 | 0,06 % | 0,78 % | 20,95 % | 63,01 % |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Cycadia (sNDA)
décision de la FDA sur Zykadia en première intention - le traitement des patients atteints de cancer du poumon métastatique non à petites cellules (NSCLC) , dont les tumeurs sont kinase lymphatique anaplasique (ALK) - positif
23/08/2017
La FDA approuve l'utilisation prolongée de Zykadia 26, mai 2017
In the thread Trading Novartis AG ADR
Die von melinda gewählte maximale Laufzeit wurde überschritten